Eli Lilly (LLY) Change in Acquisitions & Divestments (2009 - 2025)

Eli Lilly has reported Change in Acquisitions & Divestments for 17 years, with the latest figure at $132.0 million in Q4 2025.

• For the quarter ending Q4 2025, Change in Acquisitions & Divestments rose 135.71% year-over-year to $132.0 million; the trailing twelve-month figure through Dec 2025 stood at $964.0 million (up 157.75% YoY), and the FY2025 full-year result was $964.0 million, up 157.75% from the prior year.
• Change in Acquisitions & Divestments for Q4 2025 stood at $132.0 million, down from $556.1 million in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $753.4 million in Q4 2021, with the low at -$172.3 million in Q2 2023.
• Historically, Change in Acquisitions & Divestments has averaged $149.4 million across 5 years, with a median of $69.2 million in 2024.
• Annual changes were most pronounced in 2021 — Change in Acquisitions & Divestments jumped 6811.93% — and 2023, when it slumped 657.61%.
• Eli Lilly's Change in Acquisitions & Divestments stood at $753.4 million in 2021, then plunged by 65.61% to $259.1 million in 2022, then jumped by 36.16% to $352.8 million in 2023, then slumped by 84.13% to $56.0 million in 2024, then surged by 135.71% to $132.0 million in 2025.
• The last three Change in Acquisitions & Divestments figures came in at $132.0 million (Q4 2025), $556.1 million (Q3 2025), and $204.3 million (Q2 2025), per Business Quant data.